This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in New Hampshire
Licensed New Hampshire practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. New Hampshire buyers need their own professional license and NPI; the wholesaler license under RSA 318:51-a is the supplier’s obligation, not the purchaser’s, and New Hampshire’s lack of a general sales tax means there is no resale certificate to manage.
Two New Hampshire facts shape practice structure here. APRNs hold plenary prescriptive and practice authority under RSA 326-B:11, with no physician collaboration requirement. And the legislature looked hard at regenerative medicine in 2026: HB 1292 would have regulated stem cell therapies under an expanded right-to-try act, and the House sent it to interim study rather than passing it, so no state statute addresses the area today.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to New Hampshire? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | No |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 16 October 2026 |
Ordering from New Hampshire
ExaVeyra ships to licensed practices in all 50 states, New Hampshire included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active New Hampshire professional license in good standing, verifiable through the OPLC online license verification portal that covers the Board of Medicine, Board of Nursing, and Board of Pharmacy.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- No resale certificate: New Hampshire imposes no general sales or use tax, so the resale documentation other states require for purchase-for-resale has no New Hampshire equivalent.
How the state permits wholesale distribution
New Hampshire requires a license before any person, as a wholesaler or distributor of any kind named in RSA 318:51-a, supplies legend drugs or controlled drugs in or into the state, wherever the facility sits. The Office of Professional Licensure and Certification issues the license according to eligibility requirements set in rule by the pharmacy board, and licenses expire biennially on June 30 of every even-numbered year, with a 30-day duty to notify the office of any change to the application information. The regime covers prescription and controlled drugs; the board separately licenses categories such as medical gas and medical device retail distributors. The license sits with the distributor, not with the purchasing practice.
N.H. RSA 318:51-a · New Hampshire Office of Professional Licensure and Certification, Board of Pharmacy
New Hampshire regenerative-medicine law
New Hampshire has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
No New Hampshire statute addresses unapproved regenerative therapy, so federal law is the only layer. The question did reach the legislature: HB 1292 in the 2026 session would have expanded the right-to-try act to qualifying severe illnesses and regulated regenerative stem cell therapies, with consent, accreditation, advertising, and disclosure requirements. The House Judiciary Committee voted 17 to 1 to refer it for interim study, and the House did so on 5 March 2026, so nothing was enacted. Practice in this area is governed by the Medical Practice Act, the Nurse Practice Act, and the boards under the Office of Professional Licensure and Certification, alongside federal law.
How this applies to exosomes
New Hampshire has no stem cell authorization law like Florida, Texas, or Georgia, no disclosure law like California, and no documentation statute like Tennessee, and the one bill that would have regulated regenerative stem cell therapies, HB 1292 of 2026, went to interim study rather than passage. Even had it passed, its subject was stem cell therapy: exosomes are acellular extracellular vesicles, not stem cells, and no New Hampshire definition reaches them. Exosome products here are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a New Hampshire practice
Because APRNs hold plenary authority, New Hampshire supports two workable structures: an APRN-led practice that evaluates, orders, and prescribes within its own scope, and a physician-led practice that delegates conventionally. Every profession involved is administered through the Office of Professional Licensure and Certification, which supports more than fifty boards from one office in Concord, so license verification runs through a single portal.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the New Hampshire Board of Medicine may perform medical acts within their scope and are the source of any delegation to staff who do not hold independent authority. |
| NP / APRN | New Hampshire APRNs practice independently. RSA 326-B:11 defines the APRN scope to include advanced assessment, diagnosing, prescribing, and providing therapeutic measures, and grants plenary authority to possess, prescribe, administer, and dispense controlled and non-controlled drugs within scope. There is no physician collaboration or supervision requirement. |
| PA | Physician assistants, renamed physician associates under RSA chapter 328-D, need a written collaboration agreement with a New Hampshire licensed physician only when they have fewer than 8,000 post-graduate clinical hours and practice without at least one New Hampshire licensed physician in the group, practice, or health system. At 8,000 hours or more, a physician associate in a physician-free setting may apply to the Board of Medicine for a waiver of the agreement. |
| RN | Registered nurses practice under the Nurse Practice Act, RSA chapter 326-B, and may perform delegated treatments within their scope and under an order from a provider with authority to issue one. An RN does not evaluate the patient or set the treatment plan. |
Good faith examination
New Hampshire expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. Given plenary APRN authority, that provider can be an APRN. Confirm current expectations with the Board of Medicine and the Board of Nursing, since this area is governed by board interpretation rather than a single statute.
Ownership and clinic licensing
New Hampshire does not codify a corporate practice of medicine prohibition the way Texas, New York, or New Jersey do, and professional entities together with management services arrangements are the usual structures. Because the position rests on professional entity statutes and board expectations rather than a bright-line rule, published summaries disagree with one another, and ownership structure here is a question for New Hampshire counsel rather than one a guide should answer with a percentage.
Cold chain into New Hampshire
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in New Hampshire order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Manchester | Hillsborough | Largest New Hampshire market, anchoring the southern tier. |
| Nashua | Hillsborough | Border market drawing Massachusetts patients north. |
| Concord | Merrimack | Capital market, and the seat of OPLC and the licensing boards. |
| Portsmouth | Rockingham | Seacoast market with aesthetic and concierge practices. |
| Lebanon | Grafton | Upper Valley market around the Dartmouth Health system. |
- New Hampshire orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Each shipment arrives with the manufacturer’s handling instructions and the lot-specific Certificate of Analysis.
Practice types we supply in New Hampshire
New Hampshire licensing and verification
New Hampshire Board of Medicine (OPLC)
Licenses physicians and physician associates, and handles the 8,000-hour collaboration waiver.
New Hampshire Board of Nursing (OPLC)
Licenses RNs and APRNs, who hold plenary authority under RSA 326-B:11.
New Hampshire Board of Pharmacy (OPLC)
Sets the eligibility rules for the wholesaler and distributor licenses OPLC issues.
New Hampshire Department of Revenue Administration
Confirms New Hampshire has no general sales or use tax, so no resale certificate applies.
New Hampshire sourcing questions
- Does New Hampshire have a stem cell law?
- No. The closest the state has come is HB 1292 in the 2026 session, which would have expanded the right-to-try act and regulated regenerative stem cell therapies with consent, accreditation, advertising, and disclosure requirements. The House referred it for interim study on 5 March 2026, so nothing was enacted, and exosome products in New Hampshire are governed by federal law.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, in New Hampshire or anywhere else, and the FDA has issued a public safety notification on exosome products. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot documentation on every vial.
- Can a nurse practitioner run a practice in New Hampshire without a physician?
- Yes. RSA 326-B:11 gives APRNs plenary authority to assess, diagnose, prescribe, administer, and dispense controlled and non-controlled drugs within their scope, with no physician collaboration or supervision requirement. An APRN-led practice evaluates and orders within its own scope.
- What do physician associates need in place in New Hampshire?
- It depends on hours and setting. Under RSA 328-D:3-b, a physician associate with fewer than 8,000 post-graduate clinical hours who practices without a New Hampshire licensed physician in the group needs a written collaboration agreement with a physician practicing in a similar area of medicine. At 8,000 hours or more, the Board of Medicine can waive the agreement on application. A physician associate working inside a group that includes a New Hampshire licensed physician needs neither.
- Does my New Hampshire clinic need a wholesaler license to buy exosomes?
- No. The license under RSA 318:51-a is held by the wholesaler or distributor supplying drugs in or into New Hampshire, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Does New Hampshire charge sales tax on practice purchases?
- New Hampshire imposes no general sales or use tax, so there is no sales tax on the order and no resale certificate to file for purchase-for-resale. Practices with locations in other states still handle those states’ requirements for orders shipped there.
- How long does cold-chain shipping take to New Hampshire?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- N.H. RSA 318:51-a, licensing of manufacturers and wholesalers (accessed 16 October 2026)
- N.H. RSA 326-B:11, APRN scope of practice and authority (accessed 16 October 2026)
- N.H. RSA 328-D:3-b, physician assistant scope of practice (accessed 16 October 2026)
- New Hampshire General Court, HB 1292 (2026) bill status (accessed 16 October 2026)
- New Hampshire Board of Pharmacy (OPLC) (accessed 16 October 2026)
- New Hampshire Board of Medicine (OPLC) (accessed 16 October 2026)
- New Hampshire Department of Revenue Administration (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Clinical guidelinesupports: The landmark characterization standard for extracellular vesicles, the baseline this page assumes when it describes what a defensible exosome COA and lot documentation package reports.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The current revision of the MISEV standard, supporting this page’s point that EV characterization expectations are set by the field’s consensus guidelines rather than by any New Hampshire statute or the bill the legislature studied.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: The ISEV position on manufacturing, safety, and regulatory expectations for EV-based products, the context for this page’s statement that no exosome product holds FDA approval.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.